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Glaucoma is a neuropathology, often accompanied by an elevated intraocular pressure
(IOP), which can lead to blindness. Since DBA/2J mice develop glaucoma, several
studies of the physiopathology of glaucoma have been reported in this animal model.
It is also known that purinergic receptors are involved in the pathology of glaucoma
by controlling aqueous humor production and drainage and therefore controlling IOP.
There are no studies on purinergic receptors in the DBA/2J model of glaucoma and their
relation to the development of the pathology, so the aim of this study was to make an
approach to the purinergic mechanisms involved in glaucoma. All the experiments were
performed using DBA/2J and C57BL/6J mice and investigating P2Y1, P2Y2, and P2Y6
receptors. IOP measurements were made with a non-invasive rebound tonometer, and
animals were instilled with diadenosine tetraphosphate (Ap4A) and the corresponding
purinergic antagonists in order to see their effects on IOP. The expression of mRNA for
P2Y1, P2Y2, and P2Y6 purinergic receptors was carried out by quantitative real-time
PCR. Additionally, P2Y-receptor expression was performed by immunohistochemical
techniques carried out on the ciliary processes. The results showed that IOP decreases
when Ap4A was instilled and that the expressions of the analyzed purinergic receptors
were stable throughout all the ages under study in the C57BL/6J mice (control mice).
On the other hand, there were significant changes in the purinergic receptor expression
in DBA/2J suggesting that elevated IOP in these animals could be related to an increase
of P2Y2 expression and a decrease in P2Y1 receptors.
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INTRODUCTION
DBA/2J mouse strain has become a popular model for studying glaucoma, because it develops
the pathology spontaneously. DBA/2J mice contain mutations in two genes, Tyrp1 and
Gpnmb, encoding tyrosinase-related and glycosylated transmembrane proteins, respectively. These
mutations lead to pigment dispersion, iris transillumination, iris atrophy, and anterior synechia
(Anderson et al., 2002). Due to the blockade of aqueous outflow, DBA/2J mice suffer from ocular
hypertension by the age of 9 months, which is accompanied by the canonical symptoms of a
glaucoma-related death of retinal ganglion cells (RGCs), optic nerve atrophy and cupping, as well
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as visual deficits (Libby et al., 2005). The pathophysiology
of glaucoma remains in part unknown, although there are
several studies demonstrating that elevated intraocular pressure
(IOP) affects disease development, leading to a progressive
optic neuropathy characterized by functional and structural
impairment of ocular tissues that may result in the loss of vision
(Davson, 1993). This elevated IOP mainly leads to glaucoma as
a result of impeded aqueous humor outflow (Tomarev, 2001).
Aqueous humor is produced by the ciliary epithelium in the
posterior chamber of the eye and circulates through the pupil
to the anterior chamber, where it drains through the trabecular
meshwork into Schlemm’s canal and episcleral veins (Morrison
and Acott, 2003). Thus, the ciliary processes provide the pressure
inside the eye, which is maintained as a balance between the
production and the drainage of the aqueous humor throughout
the trabecular meshwork.
It is well known that purinergic P2 receptors, which are
activated by extracellular nucleotides, can be involved in
aqueous humor production and drainage and are therefore
involved in IOP control (Guzman-Aranguez et al., 2013).
P2 receptors are classified into two subfamilies: G protein-
coupled P2Y receptors and ligand-gated cation channels
called P2X receptors. So far, seven P2X subunits (P2X1-7)
and eight P2Y receptors (P2Y1,2,4,6,11,12,13,14) have been
cloned and characterized in humans, according to their
agonist sensitivity, sequence identities, and signal transduction
mechanisms (Burnstock, 2000; Abbracchio et al., 2006).
P2Y receptors contain seven hydrophobic transmembrane
domains connected by three extracellular loops and three
intracellular loops. The extracellular amino-terminus
presents sites for glycosylation and the intracellular domain
contains potential sites for phosphorylation, which may
participate in receptor desensitization and internalization. P2Y
receptors can be characterized according to their responses
to nucleotide agonists and subtype-preferring antagonists.
Adenine nucleotides, such as ADP or its synthetic analogous
2-methylthio-ADP (2-MeSADP), can activate selectively
P2Y1 receptors (Waldo and Harden, 2004), whereas uracil
nucleotides activate P2Y6 receptors (Nicholas et al., 1996).
Moreover, both adenine and uracil nucleotides (ATP and
UTP) activate equipotently P2Y2 receptors (Lazarowski et al.,
1995).
P2Y1 and P2Y2 receptors are expressed in rabbit ciliary body
epithelial cells, which may be responsible for the action of
2-MeSATP, ATPγS, as well as other P2Y agonists (Farahbakhsh
and Cilluffo, 2002). The expression of P2Y1, P2Y2, and P2Y4
receptors in bovine trabecular meshwork has also been reported
(Soto et al., 2005) as well as the presence of P2Y6 and P2Y11
receptors in rat ocular structures (Pintor et al., 2004).
The dinucleotide diadenosine tetraphosphate (Ap4A)
(Guzman-Aranguez et al., 2011) shows a hypotensive effect
when instilled topically in the eye (Fonseca et al., 2016), which
is related to an increase in the outflow of the aqueous humor
through activation of several purinergic receptors, mainly the
P2Y1 (Schachter et al., 1996; Soto et al., 2005).
Most of the experiments performed to analyze the modulation
of aqueous humor production and drainage by purinergic
receptors previously described in the scientific literature,
have been carried out on normotensive mice models or
on induced models of glaucoma. Here we characterize
the presence of P2Y1, P2Y2, and P2Y6 receptors in the
ciliary processes of the eye of control versus glaucomatous
mice and analyze the expression levels of these receptors
during aging and the development of the pathology in these
animals.
MATERIALS AND METHODS
Animals
Experiments were performed on adult female C57BL/6J (n= 30)
(control animals) and DBA/2J (n = 30) (glaucomatous animals)
mice obtained from the European distributor of Jackson
Laboratories Mice (Charles River Laboratories). All animal
maintenance and experimental procedures followed Spanish and
European guidelines for animal care in the laboratory and animal
research (Guide for the Care and Use of Laboratory Animals)
and the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research. Mice were housed (1–4 mice per cage) in
temperature and light-controlled rooms maintained according
to a 12-h/12-h light/dark cycle; all animals were fed ad libitum.
DBA/2J and C57BL/6J mice were studied at 3, 6, 9, and 12 months
of age.
All this study has been approved by the Animal Experimental
Committee of the Universidad Complutense de Madrid and
Comunidad de Madrid, reference 45/057949.9/16.
Intraocular Pressure (IOP)
Measurements
Intraocular pressure (IOP) was measured using a non-invasive
rebound tonometer (Tono-lab R©; Tiolat, OY, Helsinki, Finland).
The tonometer was fixed so that the probe tip was aligned with the
optical axis of the eye, at a distance of 1–4 mm. In order to avoid
the effect of the circadian rhythm, the IOP was always tested at
the same time of day. Six consecutive measurements were taken
for each reading, and three readings were obtained on each eye
(Fonseca et al., 2016).
In order to study the effect of Ap4A, two IOP measurements
were taken before Ap4A was instilled. A single application of 2 µl
drops with a micropipette at 100 µM was instilled once every
hour for 6 h. To study the effect of the antagonists of purinergic
receptors, these blockers were instilled in 2 µl drops with a
micropipette at 100µM 30 min before Ap4A at a concentration of
100 µM, measuring IOP in the same way as previously described
(Fonseca et al., 2016). The antagonists assayed in the current
study were pyridoxalphosphate-6-azophenyl-2’,4’-disulfonic acid
(PPADS), suramin and reactive blue 2 (RB-2, a non-selective P2
antagonists), 2’-deoxy-N6-methyladenosine 3’,5’-bisphosphate
tetrasodium salt (MRS2179, a P2Y1 antagonist), and N,N′′-1,4-
butanediylbis(N′-(3-isothiocyanatophenyl))thiourea (MRS2578,
a P2Y6 antagonist). All the doses (concentrations), volumes, and
times of measurement have been controlled according to Fonseca
et al. (2016).
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FIGURE 1 | Effect of P2 receptor antagonists on IOP reduction mediated by
Ap4A in C57BL/6J versus DBA/2J mice. Two IOP measurements were taken
before a single dose of either vehicle or 100 µM Ap4A was instilled, and 3 h
later, IOP was measured again. When indicated, purinergic antagonists, all
tested at 100 µM, were instilled 30 min before Ap4A. MRS2179 and
MRS2578 are antagonists of P2Y1 and P2Y6 receptors, respectively. “P2Y2
cocktail” contains PPADS, suramin, and RB-2. Data are the mean ± SEM of 4
mice (∗p < 0.05, ∗∗p < 0.01; one-way ANOVA with Dunnett’s multiple
comparisons test).
RNA Isolation and RT-PCR
Total RNA from isolated ciliary bodies and iris of DBA/2J
(n = 24) and C57BL/6 (n = 24) mice was extracted using
Speedtools total RNA extraction kit (Biotools, Madrid, Spain),
following the manufacturer’s instructions. After digestion with
TURBO DNase (Ambion, Austin, TX, United States), total RNA
was quantified and reverse transcribed using M-MLV reverse
transcriptase, 6 µg of random primers and 350 µM dNTPs
(Invitrogen, San Francisco, CA, United States). Due to the
small size of the tissues and in order to improve sensitivity
of PCR analysis, pre-amplification reactions were carried out
using DNA AmpliTools Master Mix (Biotools), 5 µL of the
RT product and specific commercial oligonucleotide primers for
mouse P2Y1, P2Y2, and P2Y6 receptors (Applied Biosystems).
Moreover, non-template control was amplified to check for
contamination during the procedure. Pre-amplification reactions
were performed on a 2720 Thermal Cycler (Applied Biosystems)
with the following program: initial denaturation step at 94◦C for
5 min followed by 14 cycles of amplification (94◦C for 30 s, 60◦C
for 30 s, and 72◦C for 30 s). Then, 5 µL of the pre-amplified
product diluted 1/5 in water was used for the subsequent PCR
assay. PCR reactions were identical to pre-amplification ones,
with the exception of the number of cycles, which were 40 in
the last case. Amplified PCR products were electrophoresed on
a 2% agarose gel and visualized by SYBR R© Safe DNA gel stain
(Invitrogen). DNA ladders used were GeneRuler 1 Kb and 100 bp
(Thermo Scientific).
Quantitative Real-Time PCR
Following pre-amplification, 5 µL of the each product diluted
1/5 in water were used for the subsequent quantitative real-time
FIGURE 2 | Several metabotropic P2Y receptors are simultaneously
expressed in the eye ciliary processes of C57BL/6J mice. RT-PCR expression
of P2Y1, P2Y2, and P2Y6 receptors. Molecular weights of the bands were
around 100 bp and were amplified from adult C57BL/6J mouse ciliary
processes (CP) mRNA extracts. No amplification products were observed in
parallel assays carried out without template (H2O). M: 1 Kb DNA ladder
(10000-250 pb); m: 100 bp DNA ladder (1000–1100 bp).
FIGURE 3 | Temporal pattern of P2Y1 transcript expression in ciliary
processes of C57BL/6J versus DBA/2J mice. Total RNA from ciliary
processes of either control (C57BL/6J) or glaucomatous (DBA/2J) animals of
3, 6, 9, or 12 months of age was extracted and P2Y1 mRNA was quantified
by Q-PCR as described in the Section “Materials and Methods.” Values were
normalized to the content of GAPDH transcript. Results are the mean ± SEM
of 24 animals of each strain (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 versus
same mice strain; ###p < 0.001 versus different mice strain; two-way ANOVA
with Sidak’s post-test).
PCR (Q-PCR) assay. Q-PCR reactions were carried out using
LuminoCt R© Q-PCR Readymix (Sigma–Aldrich, St. Louis, MO,
United States), 5 µL of the RT product, and specific commercial
oligonucleotide primers and TaqMan MGB probes for mouse
P2Y1, P2Y2, and P2Y6 receptors, as well as for GAPDH (all from
Applied Biosystems). Fast thermal cycling was performed using
a StepOnePlus R© Real-Time System (Applied Biosystems, Foster
City, CA, United States) as follows: denaturation, one cycle of
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FIGURE 4 | Cellular distribution of P2Y1 receptor in ciliary processes of C57BL/6J versus DBA/2J mice. Immunofluorescence images of ciliary processes from
3-month-old C57BL/6J (a), 3-month-old DBA/2J (b), and 12-month-old DBA/2J (c) mice labeled with antibodies against P2Y1 receptor (green). Nuclei were
counterstained with propidium iodide (red). (d) Negative control was carried out by substituting the P2Y1 primary antibody by the same volume of PBS/TX-100
solution. Phase-contrast and confocal images show that P2Y1 immunostaining is mainly located in non-pigmented epithelium of ciliary processes, being enhanced in
DBA/2J versus C57BL/6J at the age of 3 months. Scale bar: 20 µm.
95◦C for 20 s, followed by 40 cycles each of 95◦C for 1 s and 60◦C
for 20 s. The results were normalized as indicated by the parallel
amplification of the GAPDH housekeeping gene. Thus, Q-PCR
graphs indicate the ratio between P2Y and GAPDH transcripts
multiplied by the 10e4 factor in order to represent Y-axis values
higher than 1.
Immunohistochemistry
C57BL/6J and DBA/2J mice at 3 and 12 months of age (n = 6
animals for each group) were euthanized with an intraperitoneal
injection overdose of pentobarvital (Dolethal; Vetoquinol R©;
Especialidades Veterinarias, S.A., Alcobendas, Madrid, Spain)
and perfused pericardially with phosphate buffer saline (PBS)
followed by a solution of 4% paraformaldehyde in PBS 0.1 M, pH
7.4 at 4◦C. The eyes were enucleated and dissected with curved
forceps and sterile scissors. The anterior pole was immersed in
paraformaldehyde (PFA) fixative solution for 1 h at 4◦C and
was washed in PBS, and rinsed in 11% sucrose solution for 1 h
and 33% sucrose solution overnight at 4◦C as cryoprotection
procedure. Finally, the structures were embedded in tissue
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medium freezing medium (Tissue-Tek© OCT) using liquid N2
and vertical sections (10 µm thick) were cut on a cryostat
(Microm, Walldorf, Germany) and collected on poly-L lysine-
coated slides and stored at−20◦C until use.
Frozen sections were rinsed in PBS 1× and permeabilized
with PBS-containing 0.25% Triton X-100 (TX-100) for 30 min.
To avoid non-specific staining, sections were incubated with the
blocking solution containing 10% normal donkey serum (NDS;
Jackson ImmunoResearch, West Grove, PA, United States)
and 0.1% TX-100 in PBS for 1 h at room temperature. Then,
the following primary antibodies diluted in PBS containing
0.1% TX-100 were incubated at 4◦C overnight: goat anti-P2Y1
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, United States;
sc-15204, 1:100), rabbit anti-P2Y2 (Alomone Labs Israel,
APR-010, 1:100) goat anti-P2Y6 (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, United States; sc-15215, 1:75) diluted in
PBS-0.1% TX-100 were incubated at 4◦C overnight. Finally,
tissue sections were washed in PBS containing 0.1% TX-100
and incubated. The secondary antibody donkey anti-rabbit
Alexa Fluor 488 IgG (H+L) (Jackson ImmunoResearch, West
Grove, PA, United States) was diluted 1:200 in PBS containing
0.1% TX-0.1% for 1 h in darkness at room temperature. Nuclei
were stained with propidium iodide (red, Sigma–Aldrich,
St. Louis, MO, United States) diluted 1:500 in PBS for 10 min.
Finally, sections were rinsed and mounted in Vectashield
(Vector Laboratories, Palex Medical, Barcelona, Spain)
and coverslipped. Negative controls were carried out by
following the same procedures but, in each case, the primary
antibody was substituted by the same volume of PBS/TX-100
solution. For the analysis, the images were acquired using
a laser-scanning microscope (Zeiss LSM 5, Jena, Germany)
at 40× magnification and exported as tiff files for further
analysis.
Statistical Analysis
All data are presented as the mean ± SEM. Statistical differences
were calculated using one-way ANOVA test with Dunnett’s post-
test plotting and fitting were carried out by GraphPad Prism 6
computer program (GraphPad Software).
RESULTS
Activation of P2Y Receptors Decreases
IOP in C57BL/6J and DBA/2J Mice
Strains
Ap4A has been reported as an agonist of P2Y1, P2Y2, and P2Y6
receptors (Patel et al., 2001; Pintor et al., 2002). In a previous
study, we have demonstrated that the instillation of Ap4A was
able to significantly decrease IOP in both control C57BL/6J
and glaucomatous DBA/2J aged mice, with a maximal effect
after 3 h of treatment (Fonseca et al., 2016). In the current
study, we tested the effect of different P2Y receptor antagonists
on the IOP reduction mediated by Ap4A in 12-month-old
C57BL/6J versus DBA/2J mice (Figure 1). It was noticed that
the Ap4A effect on control animals was completely blocked by
FIGURE 5 | Temporal pattern of P2Y2 mRNA levels in ciliary processes of
C57BL/6J versus DBA/2J mice. Total RNA from ciliary processes of either
control (C57BL/6J) or glaucomatous (DBA/2J) animals of 3, 6, 9, or
12 months of age was extracted and P2Y2 mRNA was quantified by Q-PCR
as described in the Section “Materials and Methods.” GAPDH was used as a
control for differences in cDNA input. Results are the mean ± SEM of 24
animals of each strain (∗∗p < 0.01, ∗∗∗p < 0.001 versus same mice strain;
#p < 0.05, ##p < 0.01 ###p < 0.001 versus different mice strain; two-way
ANOVA with Sidak’s post-test).
either MRS2179, a P2Y1 antagonist (∗∗p < 0.005), or a cocktail
of suramin, PPADS and RB-2, which altogether inhibits P2Y2
receptor (∗p < 0.05), whereas MRS2578, a P2Y6 antagonist,
did not show a significant effect on the Ap4A hypotensive
effect. On the contrary, in glaucomatous animals, the P2Y1
antagonist did not modify the Ap4A effect, whereas either
the “P2Y2 cocktail” or the P2Y6 antagonist MRS2578 was
able to prevent the IOP fall induced by Ap4A. We have also
performed RT-PCR experiments demonstrating that P2Y1, P2Y2,
and P2Y6 transcripts were expressed in the ciliary processes
of C57BL/6J mice (Figure 2). These results suggested that
the expression levels of P2Y receptors could differ between
control and glaucomatous animals. In order to check this
possibility, we analyzed, by Q-PCR and immunohistochemistry,
the expression levels of P2Y1, P2Y2, and P2Y6 receptors in the
ciliary processes of both C57BL/6J and DBA/2J mice at different
ages.
Expression of P2Y1 Receptors in Ciliary
Processes of C57BL/6J and DBA/2J Mice
First, the expression levels of P2Y1 transcript were compared
between the control and glaucomatous mice of 3, 6, 9, and
12 months of age by Q-PCR. In C57BL/6J mice, P2Y1 mRNA
expression remained invariable during the adult life of the
animals (Figure 3, black bars). Interestingly, P2Y1 expression
in DBA/2J mice was twofold higher than in C57BL/6J animals
at 3-month-old (p = 0.005), but decreased to control values in
older mice (Figure 3, gray bars). Immunohistochemical studies
revealed that the P2Y1 receptor was widely distributed over
all in the non-pigmented epithelium of the ciliary process
of the eye in both C57BL/6 and DBA/2J mice. However,
as observed in transcript levels, P2Y1 receptor expression
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FIGURE 6 | Cellular distribution of P2Y2 receptor in ciliary processes of C57BL/6J versus DBA/2J mice. Immunofluorescence images of ciliary processes from
3-month-old C57BL/6J (a), 3-month-old DBA/2J (b), and 12-month-old DBA/2J (c) mice labeled with antibodies against P2Y2 receptor (green). Nuclei were
counterstained with propidium iodide (red). (d) Negative control carried out by substituting the P2Y2 primary antibody by the same volume of PBS/TX-100 solution.
Phase-contrast and confocal images show that the P2Y2 receptor is mainly located in the non-pigmented epithelium of ciliary processes, and its expression is
strongly increased in old DBA/2J mice compared to young animals. Scale bar: 20 µm.
was enhanced in 3-month-old DBA/2J animals compared to
12-month-old ones and also compared to 3-month-old C57BL/6
mice (Figure 4).
Expression of P2Y2 Receptors in Ciliary
Processes of C57BL/6J and DBA/2J Mice
As shown for P2Y1 transcript, P2Y2 mRNA expression remained
invariable during the adult life of C57BL/6J mice (Figure 5, black
bars). However, a pathology-dependent rise in P2Y2 transcript
levels was found in glaucomatous mice, reaching a sixfold
increase in 12-month-old DBA/2J mice compared to control
ones (p = 0.005), although a significant increase was already
observed in 6-month-old mice (Figure 5, gray bars). P2Y2
protein was also found in the non-pigmented epithelium of
the ciliary processes of both C57BL/6J and DBA/2J animals,
although, as expected, a huge increment in the fluorescent
signal coupled to P2Y2 receptor was found in 12-month-
old DBA/2J mice compared to young animals of both strains
(Figure 6).
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FIGURE 7 | Temporal pattern of P2Y6 transcript expression in ciliary
processes of C57BL/6J versus DBA/2J mice. Total RNA from ciliary
processes of either control (C57BL/6J) or glaucomatous (DBA/2J) animals of
3, 6, 9, or 12 months of age was extracted and P2Y6 mRNA was quantified
by Q-PCR as described in the Section “Materials and Methods.” Values were
normalized to the content of GAPDH transcript. Results are the mean ± SEM
of 24 animals of each strain (∗∗∗p < 0.001 versus same mice strain;
#p < 0.05, ###p < 0.001 versus different mice strain; two-way ANOVA with
Sidak’s post-test).
Expression of P2Y6 Receptors in Ciliary
Processes of C57BL/6J and DBA/2J Mice
The expression pattern of P2Y6 receptors was very similar
to that observed for P2Y2 receptors. As shown in Figure 7,
P2Y6 transcript levels remained constant in C57BL/6J mice
(black bars), but an age-dependent increase in P2Y6 mRNA
was observed in DBA/2J mice (gray bars). This increment was
significant in 6-month-old animals and was progressively rising
until reaching a sixfold increase in 12-month-old DBA/2J mice
compared to control ones (p = 0.005). Immunohistochemical
studies confirmed that the P2Y6 receptor was also located in
the non-pigmented epithelium of the ciliary body of the eye of
both mice strains. Moreover, as observed in transcript levels,
P2Y6 receptor expression was significantly higher in 12-month-
old DBA/2J animals compared to young ones and also compared
to young C57BL/6 mice (Figure 8).
DISCUSSION
The existence of nucleotides in the aqueous humor (Mitchell
et al., 1998; Pintor et al., 2003), as well as the participation of
P2 purinergic receptors in the regulation of IOP, has already
been described in the scientific literature (Crooke et al., 2008).
Mono and dinucleotides, both in the µM range, are able to
activate P2 receptors, which in turn modify both the synthesis
and drainage of the aqueous humor. In normotensive animal
models, P2Y1 and P2Y2 receptors are located in the trabecular
meshwork and the ciliary body, respectively (Soto et al., 2005;
Martin-Gil et al., 2012). When the activation of P2Y1 receptors
is carried out by Ap4A in the trabecular meshwork, the observed
effect is a reduction in IOP (Soto et al., 2005), whereas the
activation of P2Y2 receptors in the ciliary body produces a
hypertensive effect (Martin-Gil et al., 2012). P2Y2 receptors exert
this effect by increasing the presence of Aquaporin-1 in the ciliary
body epithelial cell membranes (Martin-Gil and Pintor, 2010;
Pintor et al., 2011). Finally, the activation of P2Y6 receptor by
molecules such as uridine diphosphate (UDP), reduces IOP in the
New Zealand normotensive model (Markovskaya et al., 2008).
Ap4A is a molecule present in the aqueous humor of animal
models such as rabbits or mice (Pintor et al., 2003), but is also
present in normal and glaucomatous human patients (Castany
et al., 2011). Therefore, this dinucleotide seems to be involved
in the pathophysiology of glaucoma, mainly by acting on P2
purinergic receptors. In this sense, the release of Ap4A is
produced by the activation of a pressure sensor, a TRPV4 channel,
which is activated by the abnormal IOP often associated to
glaucoma (Pintor et al., 2011). The TRPV4-induced Ap4A release
will stimulate mainly the P2Y2 receptor present in the ciliary
body, which mobilizes Aquaporin-1 from intracellular reservoirs
to the plasma membrane of the ciliary epithelium (Martin-Gil
and Pintor, 2010). This increase in the aquaporins facilitates the
production of aqueous humor contributing to the elevation of
IOP and therefore priming the described process.
In this current study, using a glaucoma animal model, we
have analyzed the expression levels of three P2Y metabotropic
receptors (P2Y1, P2Y2, and P2Y6), which are known to be
activated by Ap4A (Guzman-Aranguez et al., 2007), in the
ciliary body and iris of control (C57BL/6) and glaucomatous
(DBA/2J) mice. Our results demonstrate that control animals
express constant levels of P2Y1, P2Y2, and P2Y6 receptors
throughout their lives, in clear contrast to the glaucomatous
strain, where more remarkable changes are observed. In this
sense, P2Y1 receptor expression is significantly reduced at
both mRNA and protein levels in aged DBA/2J mice. On the
contrary, however, P2Y2 and P2Y6 receptor expressions are
enhanced in aged DBA/2J mice, correlating in time with the
pathology development. Similar differences between control and
glaucomatous mice have also been found when analyzing the
retinal electrophysiology in both strains, observing a gradual
ganglion cell death in DBA/2J model (Perez de Lara et al., 2014).
Moreover, the retinal ATP released increases in the glaucomatous
mouse, but not in the control one when the pathology is fully
established (12 months of age). In addition, the expression
of the vesicular nucleotide transporter (VNUT) is significantly
increased during the development of glaucoma in DBA/2J mice,
reaching maximal levels at 12 months of age (Perez de Lara et al.,
2015). Altogether, this evidence suggests that the alteration in
the purinergic system observed in the DBA/2J is related to the
pathology development and not to mice aging.
We have also established that micromolar concentrations
of Ap4A significantly reduce IOP in DBA/2J mice, once the
pathology is fully developed. Moreover, a chronic treatment with
the dinucleotide for 3 months is able to ameliorate the elevation
in IOP in the glaucomatous mice in a very significant manner
(Fonseca et al., 2016). These results indicate that the predominant
physiological effect of Ap4A is the reduction of IOP, although the
expression of both P2Y2 and P2Y6 in DBA/2J mice is increased
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FIGURE 8 | Cellular distribution of P2Y6 receptor in ciliary processes of C57BL/6J versus DBA/2J mice. Immunofluorescence images of ciliary processes from
3-month-old C57BL/6J (a), 3-month-old DBA/2J (b), and 12-month-old DBA/2J (c) mice labeled with antibodies against P2Y6 receptor (green). Nuclei were
counterstained with propidium iodide (red). (d) Negative control was carried out by substituting the P2Y6 primary antibody by the same volume of PBS/TX-100
solution. Phase-contrast and confocal images show that the P2Y6 receptor is mainly located in the non-pigmented epithelium of ciliary processes, and its expression
is increased in 12-month-old DBA/2J mice compared to 3-month-old animals. Scale bar: 20 µm.
and both receptors mediate opposite effects on IOP (Fonseca
et al., 2016).
Previous studies reported that P2Y2 receptor activation in
the ciliary body exerted a hypertensive effect on IOP, which
could be inhibited by antagonism or silencing of that receptor
(Martin-Gil et al., 2012). The hypertensive role of the P2Y2
receptor in the ciliary body correlated well with the abnormally
elevated concentration of Ap4A found in glaucoma patients,
as previously commented (Castany et al., 2011). However, the
topical application of this dinucleotide reduces IOP, so its use in
the treatment of glaucoma cannot be discarded (Fonseca et al.,
2016).
In our experimental model, the reduction in the expression
of the P2Y1 receptor in glaucomatous mice could produce
an elevation in IOP, since the treatment with the specific
antagonist MRS2179 prevented the hypotensive effect of Ap4A
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(Fonseca et al., 2016). An increase P2Y2 expression could have
similar consequences, since its activation exerted a hypertensive
effect (Fonseca et al., 2016). Thus, the pathology-related
increased in P2Y2 receptor expression and its activation by
endogenous Ap4A could justify high IOP values measured in the
glaucomatous mice. Interestingly, exogenous applications of high
doses of Ap4A have hypotensive effects, probably by activating
the P2Y6 receptor, which is elevated in the glaucomatous mice.
Noteworthy is that the high Ap4A concentration (about 300 nM)
found in the aqueous humor of glaucoma patients is unable
to reduce IOP, probably because this concentration is enough
to stimulate the hypertensive P2Y2 receptor, but insufficient
to activate the hypotensive P2Y6, which requires micromolar
concentrations (Guzman-Aranguez et al., 2007). Further studies
will be necessary to clarify this refined equilibrium.
The pathogenesis of glaucoma is not fully understood, but
most of the studies indicate that the level of IOP is linked
to RGC’s death (Hollands et al., 2013). The rise in IOP
causes mechanical stress and strain affecting eye posterior
structures such as the lamina cribrosa and adjacent tissues,
thus causing the deformation by compression of the lamina
cribrosa. Consequently, the optic nerve axonal damage reduces
the retrograde axonal transport (Burgoyne et al., 2005). This
process produces the RGC’s death and the subsequent blindness.
Slowing disease progression, by reducing IOP, can be suggested
according to the changes in the expression of P2Y receptors
sensitive to the dinucleotide Ap4A presented in this manuscript.
A previous study has already proved the hypotensive effect of this
compound on the DBA/2J glaucoma model (Fonseca et al., 2016).
Therefore, the application of Ap4A may help to reduce IOP in
humans if the changes in the P2Y receptors are similar to the ones
described in the glaucomatous mice.
In summary, we have demonstrated that the expression of
some P2Y receptors, P2Y1, P2Y2, and P2Y6, changes during the
development of the glaucomatous pathology in a mouse model.
The prevalence of the P2Y2 receptor between 9 and 12 months
of age, together with the rise in Ap4A concentration, may be
a contributing factor that helps explain why the pressure is
abnormally elevated when the pathology is fully established.
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